HUTCHMED Confirms ELUNATE® And SULANDA® Remain On China's National Reimbursement Drug List Under Existing Terms
Portfolio Pulse from Benzinga Newsdesk
HUTCHMED (China) Limited has confirmed that its drugs ELUNATE® and SULANDA® will remain on China's National Reimbursement Drug List (NRDL) for 2024 under the same terms as the current agreement. This continuation ensures that the company's products will still be covered by China's national healthcare insurance, potentially maintaining the drugs' market presence and sales in the region.
December 13, 2023 | 6:44 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HUTCHMED's drugs ELUNATE® and SULANDA® will continue to be included in China's NRDL for 2024, which is likely to support the company's revenue stability in the Chinese market by ensuring continued insurance coverage for these drugs.
The inclusion of HUTCHMED's drugs on the NRDL is crucial for maintaining sales in China, as it ensures that the drugs are covered by national healthcare insurance. This news is likely to be viewed positively by investors as it removes uncertainty regarding the drugs' reimbursement status and supports the company's financial outlook in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100